[go: up one dir, main page]

MX2020003381A - Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. - Google Patents

Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.

Info

Publication number
MX2020003381A
MX2020003381A MX2020003381A MX2020003381A MX2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A
Authority
MX
Mexico
Prior art keywords
tnf
necrosis factor
tumor necrosis
composition
same
Prior art date
Application number
MX2020003381A
Other languages
English (en)
Inventor
Tae-Hwe Heo
Kye Jung Shin
Original Assignee
Ilab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilab filed Critical Ilab
Publication of MX2020003381A publication Critical patent/MX2020003381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a: un derivado de la 4-benzopiranona y una sal, un disolvente, un racemato o un estereoisómero de la misma aceptable desde el punto de vista farmacéutico; una composición para prevenir, aliviar o tratar las enfermedades relacionadas con el TNF, que contiene lo mismo que un ingrediente activo; y un método para tratar las enfermedades relacionadas con el TNF, una composición reactiva para inhibir el TNF y un método para inhibir el TNF, todos los cuales usan lo mismo. Las composiciones pueden administrarse por vía oral para no causar efectos secundarios en las inyecciones, no causan tolerancia inmunológica y pueden inhibir eficazmente la actividad del TNF al estar ligadas directamente al TNF, facilitando al mismo tiempo la administración conjunta con una preparación oral convencional y el control de la dosis.
MX2020003381A 2017-10-19 2018-07-12 Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. MX2020003381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170135899A KR101934651B1 (ko) 2017-10-19 2017-10-19 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법
PCT/KR2018/007922 WO2019078452A1 (ko) 2017-10-19 2018-07-12 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법

Publications (1)

Publication Number Publication Date
MX2020003381A true MX2020003381A (es) 2020-08-03

Family

ID=65021450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003381A MX2020003381A (es) 2017-10-19 2018-07-12 Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.

Country Status (11)

Country Link
US (2) US11504349B2 (es)
EP (1) EP3699174B1 (es)
JP (3) JP2020536977A (es)
KR (1) KR101934651B1 (es)
CN (2) CN111315730A (es)
AU (1) AU2018353722C1 (es)
BR (1) BR112020007826A2 (es)
CA (1) CA3074993C (es)
MX (1) MX2020003381A (es)
WO (1) WO2019078452A1 (es)
ZA (1) ZA202001887B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101934651B1 (ko) * 2017-10-19 2019-01-02 가톨릭대학교 산학협력단 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법
KR102379145B1 (ko) * 2019-07-25 2022-03-28 서울대학교 산학협력단 PICALM 저해제 및 mTORC1 저해제를 포함하는 당뇨병 매개 신경퇴행성질환의 예방, 개선 또는 치료용 조성물
KR20210026308A (ko) 2019-08-29 2021-03-10 (주)아이랩 벤조피라논 화합물의 염 및 결정형, 이의 제조 방법, 및 이를 포함하는 약학적 조성물
KR20210036162A (ko) * 2019-09-25 2021-04-02 (주)아이랩 벤조피라논 화합물의 결정형, 이의 제조 방법, 및 이를 포함하는 약학적 조성물
KR102105483B1 (ko) * 2019-10-23 2020-04-28 가톨릭대학교 산학협력단 테트라하이드로파파베린 및 il-6 억제제를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법
CN110898052A (zh) * 2019-12-21 2020-03-24 贵州中医药大学 山萘酚在制备治疗脓毒症药物中的应用
KR102379963B1 (ko) 2020-04-20 2022-03-29 (주)아이랩 벤조피라논 화합물의 제조 방법 및 이에 사용되는 신규한 중간체
WO2022010150A1 (ko) 2020-07-07 2022-01-13 (주)아이랩 신규한 tnf 활성 억제제 화합물 및 이의 약학적으로 허용가능한 염
WO2022140667A2 (en) * 2020-12-23 2022-06-30 Icahn School Of Medicine At Mount Sinai Method for treating crohn's disease
CN112939917B (zh) * 2021-02-08 2023-08-22 中山大学 一种黄酮类化合物的制备方法
CN113214351B (zh) * 2021-04-09 2021-11-30 华南师范大学 胡芦巴蛋白及其分离提取方法和在制备骨髓hsc清除辅助剂中的应用
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
JP2024525235A (ja) * 2021-07-20 2024-07-10 上海椿安生物医薬科技有限公司 外用抗炎症カップリング化合物薬物及びその製造方法並びに使用
CN114989123B (zh) * 2022-05-18 2024-05-31 长江大学 黄酮-3-羧酸类化合物、含有该化合物的杀菌组合物及用途
CN114788875B (zh) * 2022-05-25 2023-05-30 中国医学科学院放射医学研究所 一种激活Hippo通路的超分子纳米药物及其制备方法与应用
CN116370452A (zh) * 2022-12-15 2023-07-04 山东大学 萝卜硫素在缓解糖尿病性心肌病中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3715779A1 (de) * 1987-05-12 1988-11-24 Kali Chemie Pharma Gmbh Flavon-3-carbonsaeure-verbindungen sowie verfahren, zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU2001261006A1 (en) * 2000-03-28 2001-10-08 Chugai Seiyaku Kabushiki Kaisha Benzopyranes useful as tnf alpha inhibitors
JP2004505094A (ja) * 2000-07-31 2004-02-19 ユニバーシティ・オブ・メリーランド，　ボルティモア 免疫調節化合物
DE60132702T2 (de) * 2000-08-11 2009-03-19 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
KR20080013162A (ko) * 2006-08-07 2008-02-13 한국과학기술연구원 용액상 평행 조합화학을 이용한 크로몬-3-카복실산유도체의 제조방법
EP2112145A1 (en) * 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
KR101263356B1 (ko) 2011-02-23 2013-05-16 정종문 항염증용 식품 조성물
KR101640284B1 (ko) 2013-05-09 2016-07-15 가톨릭대학교 산학협력단 메트포민과 퀘르세틴을 유효성분으로 함유하는 면역 질환의 예방 또는 치료용 조성물
KR20160101732A (ko) 2015-02-17 2016-08-26 유한회사한풍제약 포도잎 추출물 또는 이로부터 분리한 퀘르세틴-3-o-글루쿠로니드를 유효성분으로 함유하는 뇌질환의 예방, 개선 또는 치료를 위한 조성물
KR101746286B1 (ko) 2015-10-13 2017-06-12 가톨릭대학교 산학협력단 케르세틴-3-o-자이로사이드를 유효성분으로 포함하는 면역 증강용 조성물
KR101934651B1 (ko) * 2017-10-19 2019-01-02 가톨릭대학교 산학협력단 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법

Also Published As

Publication number Publication date
US20230099574A1 (en) 2023-03-30
RU2020114870A3 (es) 2021-11-19
US20200246304A1 (en) 2020-08-06
BR112020007826A2 (pt) 2020-10-20
EP3699174B1 (en) 2025-11-12
AU2018353722B2 (en) 2021-07-29
JP2020536977A (ja) 2020-12-17
US11504349B2 (en) 2022-11-22
KR101934651B1 (ko) 2019-01-02
WO2019078452A1 (ko) 2019-04-25
EP3699174A4 (en) 2021-11-10
AU2018353722A1 (en) 2020-04-23
CN111315730A (zh) 2020-06-19
CA3074993A1 (en) 2019-04-25
ZA202001887B (en) 2021-06-30
NZ763267A (en) 2023-08-25
AU2018353722C1 (en) 2022-10-27
US11850230B2 (en) 2023-12-26
JP2022092052A (ja) 2022-06-21
CA3074993C (en) 2022-08-16
RU2020114870A (ru) 2021-11-19
EP3699174A1 (en) 2020-08-26
CN120478335A (zh) 2025-08-15
JP2024147607A (ja) 2024-10-16

Similar Documents

Publication Publication Date Title
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
CL2019003091A1 (es) Terapia de combinación.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
MX2019003095A (es) Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk.
HK1247835A1 (zh) 甲状旁腺功能减退症的治疗
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20140086A (es) Tratamientos de combinación para hepatitis c
MX2013012588A (es) Inhibidores de cinasa.
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
WO2015035410A8 (en) Cancer therapy
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos